Novo Nordisk A S annual ebitda
2022
2023
2024
2025
Novo Nordisk A S EBITDA Growth & History (NVO)
Novo Nordisk A S's calculated EBITDA was kr142.32B for fiscal 2025.
View full Novo Nordisk A S company overviewNovo Nordisk A S annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | kr142.32B | kr5.44B | +3.97% |
| 2024 | 2024-12-31 | kr136.88B | kr27.02B | +24.60% |
| 2023 | 2023-12-31 | kr109.86B | kr28.50B | +35.03% |
| 2022 | 2022-12-31 | kr81.36B | — | — |
Novo Nordisk A S quarterly ebitda
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | kr28.38B | −kr15.22B | −34.91% |
| Q1 2026 | 2026-03-31 | kr69.21B | — | — |
| Q4 2025 | 2025-12-31 | kr37.30B | — | — |
| Q3 2025 | 2025-09-30 | kr31.44B | — | — |
| Q2 2025 | 2025-06-30 | kr43.60B | — | — |
Novo Nordisk A S ebitda trends
Between the periods ended 2022-12-31 and 2025-12-31, Novo Nordisk A S's ebitda increased from kr81.36B to kr142.32B, a change of kr60.96B. The latest reported quarter, Q2 2026, shows kr28.38B.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novo Nordisk A S source filings ↗Community posts
Novo licenses early-stage weekly obesity pill for $300 million upfront
Novo Nordisk ($NVO) has agreed to license Hengrui Pharma’s HRS-1596, an experimental oral medicine targeting both GLP-1 and GIP receptors. The agreement includes $300 million upfront within a potential $2.6 billion total, with the balance d ...
Novo Nordisk sets new pipeline and manufacturing ambitions
Novo Nordisk ($NVO) outlined ambitions to launch more than five major new medicines by 2030 and generate over DKK150 billion in risk-adjusted sales from its current pipeline by 2035. It also intends to enter or complete at least five Phase ...
Novo’s weekly growth-hormone treatment gains another European recommendation
Novo Nordisk ($NVO) received a positive European advisory opinion for once-weekly Sogroya in children with idiopathic short stature and persistent growth disturbance. The proposed expansion is supported by the REAL8 study, which found the w ...
Novo Nordisk receives positive European opinion for hemophilia treatment
Novo Nordisk ($NVO) received a positive recommendation from the European Medicines Agency’s human medicines committee for FREHEMGO, its denecimig treatment for hemophilia A. The proposed indication covers adults and children, including pati ...
Novo Nordisk reports positive STEP Young results in children aged 6 to under 12
Novo Nordisk announced first STEP Young Phase 3 results on 7 September 2026. Trial design and outcome The randomised, double-blind study involved 165 children aged 6 to under 12, comparing weekly semaglutide with placebo. Both groups receiv ...
